Potent peroxisome proliferator-activated receptor (PPARalpha) activator. Activates also PPARgamma but not PPARdelta.
Potent anti-hypercholesterolemic agent.
Hypolipidemic compound. Lipogenesis inducer.
Causes increased cell proliferation and decreased apoptosis.
Anti-inflammatory. Inhibits NF-kappaB transcriptional activity and decreases the inflammatory response by reducing the production of inflammatory cytokines (TNF-alpha, IL1beta). Reduces oxidative stress.
Increases fatty acid oxidation.
Directly affects insulin signaling. Increases glucose uptake.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 2 years after receipt when stored at -20°C.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
A potent antihypercholesterolemic agent: (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643): A.A. Santilli, et al.; Experientia 30, 1110 (1974)
The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes: D.E. Moody & J.K. Reddy; Am. J. Pathol. 90, 435 (1978)
Peroxisome proliferation and hepatocarcinogenesis: M.S. Rao & J.K. Reddy; Carcinogenesis 8, 631 (1987)
Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids: A. Schmidt, et al.; Mol. Endocrinol. 6, 1634 (1992)
Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators: R.A. Roberts; Ann. N. Y. Acad. Sci. 804, 588 (1996) (Review)
The PPARalpha-leukotriene B4pathway to inflammation control: P.R. Devchand, et al.; Nature 384, 39 (1996)
Peroxisome proliferator-activated receptors a and g are activated by indomethacin and other non-steroidal anti-inflammatory drugs: J.M. Lehmann, et al.; J. Biol. Chem. 272, 3406 (1997)
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta: B.M. Forman, et al.; PNAS 94, 4312 (1997)
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators: B. Staels, et al.; Nature 393, 790 (1998)
Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48: D. Lindén, et al.; J. Biol. Chem. 277, 23044 (2002)
Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart: B.N. Finck & D.P. Kelly; J. Mol. Cell Cardiol. 34, 1249 (2002) (Review)
WY-14643 and 9- cis-retinoic acid induce IRS-2/PI 3-kinase signalling pathway and increase glucose transport in human skeletal muscle cells: differential effect in myotubes from healthy subjects and Type 2 diabetic patients: K. Bouzakri, et al.; Diabetologia 47, 1314 (2004)
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643: M. Collino, et al.; Free Radic. Biol. Med. 41, 579 (2006)
Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643: P. Zahradka; Cardiovasc. Drug Rev. 25, 99 (2007) (Review)
PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators; F.J. Gonzalez & Y.M. Shah; Toxicology 246, 2 (2008)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|